ATOS
Income statement / Annual
Last year (2024), Atossa Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Atossa Therapeutics, Inc.'s net income was -$25.50 M.
See Atossa Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.76 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$44.20 K
|
$128.99 K
|
$303.48 K
|
$132.41 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$44.20 K
|
-$128.99 K
|
-$303.48 K
|
-$130.65 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-74.32
|
| Research and Development Expenses |
$14.12 M
|
$17.33 M
|
$15.08 M
|
$9.21 M
|
$6.61 M
|
$7.13 M
|
$4.21 M
|
$2.33 M
|
$770.43 K
|
$2.36 M
|
| General & Administrative Expenses |
$13.50 M
|
$14.04 M
|
$12.61 M
|
$11.31 M
|
$8.00 M
|
$10.62 M
|
$7.22 M
|
$4.86 M
|
$6.48 M
|
$8.85 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.42 M
|
| Selling, General & Administrative Expenses |
$13.50 M
|
$14.04 M
|
$12.61 M
|
$11.31 M
|
$8.00 M
|
$10.62 M
|
$7.22 M
|
$4.86 M
|
$6.48 M
|
$10.27 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$486.55 K
|
$29.30 K
|
$154.00
|
$718.97 K
|
$0.00
|
| Operating Expenses |
$27.62 M
|
$31.38 M
|
$27.69 M
|
$20.52 M
|
$14.61 M
|
$17.27 M
|
$11.43 M
|
$7.19 M
|
$7.25 M
|
$12.63 M
|
| Cost And Expenses |
$27.62 M
|
$31.38 M
|
$27.69 M
|
$20.52 M
|
$14.61 M
|
$17.27 M
|
$11.43 M
|
$7.19 M
|
$7.25 M
|
$12.76 M
|
| Interest Income |
$4.05 M
|
$4.34 M
|
$877.00 K
|
$6.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$192.82 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$17.00 K
|
$23.00 K
|
$8.00 K
|
$23.00 K
|
$47.00 K
|
$52.79 K
|
$44.20 K
|
$128.99 K
|
$303.48 K
|
$272.63 K
|
| EBITDA |
-$27.60 M |
-$31.35 M |
-$27.68 M |
-$20.50 M |
-$14.56 M |
-$17.21 M |
-$11.39 M |
-$7.80 M |
-$6.37 M |
-$12.49 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-7102.38
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-7257.46
|
| Total Other Income/Expenses Net |
$2.12 M
|
$1.28 M
|
$731.00 K
|
-$85.00 K
|
-$3.22 M
|
$25.65 K
|
$29.30 K
|
-$473.41 K
|
$0.00
|
$431.00
|
| Income Before Tax |
-$25.50 M
|
-$30.09 M
|
-$26.96 M
|
-$20.61 M
|
-$17.83 M
|
-$17.24 M
|
-$11.40 M
|
-$8.12 M
|
-$6.37 M
|
-$12.76 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-7257.22
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$29.30 K
|
$0.00
|
-$1.76 M
|
$0.00
|
| Net Income |
-$25.50 M
|
-$30.09 M
|
-$26.96 M
|
-$20.61 M
|
-$17.83 M
|
-$17.24 M
|
-$11.40 M
|
-$8.12 M
|
-$6.37 M
|
-$15.76 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-8964.92
|
| EPS |
-0.2 |
-0.24 |
-0.21 |
-0.18 |
-1.97 |
-2.03 |
-2.74 |
-8.33 |
-25.93 |
-99.79 |
| EPS Diluted |
-0.2 |
-0.24 |
-0.21 |
-0.18 |
-1.97 |
-2.03 |
-2.74 |
-8.33 |
-25.93 |
-99.79 |
| Weighted Average Shares Out |
$125.86 M
|
$126.08 M
|
$126.62 M
|
$116.95 M
|
$11.31 M
|
$8.50 M
|
$4.16 M
|
$974.77 K
|
$245.61 K
|
$157.93 K
|
| Weighted Average Shares Out Diluted |
$125.86 M
|
$126.08 M
|
$126.62 M
|
$116.95 M
|
$11.31 M
|
$8.50 M
|
$4.16 M
|
$974.77 K
|
$245.61 K
|
$157.93 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
